<?xml version="1.0" encoding="UTF-8"?>
<!-- Dublin Core rendering of 638b31e3-ec3e-424c-ac12-53d5ed2fdb73, generated by folio-assistant-core/scripts/dc-render.ts. Do not edit. -->
<metadata xmlns="https://litlfred.github.io/folio-assistant-core/v0/ns/dspace/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <dcterms:creator>Khadijeh Ezoji</dcterms:creator>
  <dcterms:creator>Mohsen Yaghoubi</dcterms:creator>
  <dcterms:creator>Marzieh Nojomi</dcterms:creator>
  <dcterms:creator>Sussan Mahmoody</dcterms:creator>
  <dcterms:creator>Seyed Mohsen Zahraie</dcterms:creator>
  <dcterms:creator>Maziar Moradi-Lakeh</dcterms:creator>
  <dcterms:creator>Sedigheh R. Tabatabaei</dcterms:creator>
  <dcterms:creator>Abdollah Karimi</dcterms:creator>
  <dcterms:spatial>Cairo</dcterms:spatial>
  <dc:date>2026-04-22T12:04:21Z</dc:date> <!-- dc.date.accessioned -->
  <dcterms:available xsi:type="dcterms:W3CDTF">2026-04-22T12:04:21Z</dcterms:available>
  <dcterms:issued xsi:type="dcterms:W3CDTF">2019-10-29</dcterms:issued>
  <dcterms:abstract>Background:
Pneumococcal disease caused by Streptococcus pneumoniae results in considerable mortality and morbidity. Pneumococcal conjugate vaccines (PCV), such as PCV-13, can prevent invasive pneumococcal disease and avoid disability and death. The cost of introducing PCV-13 in childhood immunization schedules should be assessed against the cost of pneumococcal diseases for each community.
Aims:
This study aimed to evaluate the cost–effectiveness of introducing PCV-13 in the national immunization programme for children under 5 years in the Islamic Republic of Iran.
Methods:
The TRIVAC decision support model was used to estimate total costs of introducing PCV-13 and the disability-adjusted life years (DALYs)averted. The main pneumococcal diseases were considered—pneumonia, meningitis, acute otitis media, and non-pneumonia, non-meningitis infections—in terms of hospital admissions, outpatient visits and deaths. Local data were used to estimate costs.
Results:
Pneumococcal disease is estimated to affect 18 713 211 children under 5 years (519 412 pneumonia, 18 148 116 acute otitis media, 6884 meningitis, and 38 799 non-pneumonia, non-meningitis)in 10 years (2014–2023)without use of the vaccine. Introduction of PCV-13 would prevent 4 900 084 cases of pneumococcal disease (190 849 pneumonia, 4 692 450 acute otitis media, 2529 meningitis, and 14 256 non-pneumonia, non-meningitis). Pneumococcal infection would cause 287 950 hospital admissions and 29 399 deaths; vaccination could avert 105 802 hospital admissions and 9997 deaths. The incremental cost–effectiveness was estimated to be US$ 1890 and US$ 1538 per averted DALY for the government and society respectively.
Conclusion:
According to WHO-recommended thresholds for interpreting cost–effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective</dcterms:abstract>
  <dc:description>697</dc:description> <!-- dc.description.endpage -->
  <dc:description>686</dc:description> <!-- dc.description.startpage -->
  <dc:identifier>https://doi.org/10.26719/emhj.19.039</dc:identifier> <!-- dc.identifier.doi -->
  <dc:identifier>1020-3397</dc:identifier> <!-- dc.identifier.issn -->
  <dc:identifier>1687-1634 (Online)</dc:identifier> <!-- dc.identifier.issn -->
  <dcterms:identifier xsi:type="dcterms:URI">https://iris.who.int/handle/10665/385346</dcterms:identifier>
  <dcterms:language>English</dcterms:language>
  <dcterms:language xsi:type="dcterms:RFC4646">en</dcterms:language>
  <dcterms:publisher>World Health Organization. Regional Office for the Eastern Mediterranean</dcterms:publisher>
  <dc:relation>Eastern Mediterranean Health Journal</dc:relation> <!-- dc.relation.ispartofjournal -->
  <dc:relation>10</dc:relation> <!-- dc.relation.issue -->
  <dc:relation>25</dc:relation> <!-- dc.relation.volume -->
  <dcterms:rights>CC BY-NC-SA 3.0 IGO</dcterms:rights>
  <dc:rights>World Health Organization</dc:rights> <!-- dc.rights.holder -->
  <dc:rights>https://creativecommons.org/licenses/by-nc-sa/3.0/igo</dc:rights> <!-- dc.rights.uri -->
  <dcterms:subject xsi:type="dcterms:MESH">Pneumococcal Infections</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH">Pneumococcal Vaccines</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH">Vaccination</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH">Health Care Costs</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH">Health Expenditures</dcterms:subject>
  <dc:subject>prevention and control</dc:subject> <!-- dc.subject.meshqualifier -->
  <dc:subject>economics</dc:subject> <!-- dc.subject.meshqualifier -->
  <dc:subject>immunology</dc:subject> <!-- dc.subject.meshqualifier -->
  <dcterms:title>Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran</dcterms:title>
  <dcterms:type>Journal articles</dcterms:type>
</metadata>
